News | November 07, 2024
JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Stable profits, low leverage to keep credit profiles comfortable
Konieczny has served as Interim CEO since April 2024
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Expect the international business including CDMO business to pick-up in the second half of the financial year
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
Subscribe To Our Newsletter & Stay Updated
